Fzata, Inc. Secures Major NIH Grant for IBS Treatment
Fzata, Inc. Secures Major NIH Grant for IBS Treatment
Fzata, Inc. is thrilled to announce that it has been awarded a substantial five-year grant from the National Institutes of Health (NIH), totaling up to $7 million, along with in-kind contributions. This UG3/UH3 non-dilutive grant aims to advance the development of their innovative drug candidate, BioPYM™ FZ006, specifically targeting chronic visceral pain associated with inflammatory bowel syndrome (IBS).
Key Elements of the NIH Grant
The NIH National Institute of Neurological Disorders and Stroke (NINDS) will provide funding for critical studies required to bring FZ006 to the forefront of IBS treatment options. This grant will facilitate several essential processes, including IND-enabling studies, GLP toxicology assessments, cGMP manufacturing, and the design and execution of Phase 1 clinical trials.
Dr. Zhiyong Yang's Vision
Dr. Zhiyong Yang, the President and CEO of Fzata, shared his insights on the significance of this funding, stating, "Chronic visceral pain linked to IBS represents a serious unmet healthcare need affecting a large population. Approximately 10 to 15 percent of the American population endure severe pain without sufficient treatment alternatives. Traditional opioid treatments pose addiction risks, creating a critical demand for a safe, non-addictive solution. Our hope with FZ006 is to emerge as the pioneering option for effectively managing chronic abdominal pain. We are eager to collaborate with our talented team at UMB and NINDS in this transformative endeavor for IBS patients and their families."
Collaboration with Academic Institutions
Fzata's partnership with the University of Maryland, Baltimore (UMB) marks an essential step forward in this project. Phil Robilotto, DO, MBA, from UMB emphasized the value of this collaboration, stating, "This NIH award is an incredible opportunity for Fzata, recognized as one of UMB’s startup portfolio companies. The funded work will leverage knowledge and resources from UMB's scientific community to elevate Fzata's innovative technology, addressing significant medical needs." He also mentioned the promising developments surrounding their pipeline, including another drug candidate, FZ002, which targets C. difficile infections, set to begin human clinical trials soon.
The Future of Therapeutics with BioPYM™
About Fzata, Inc.: The company has pioneered a cutting-edge therapeutics platform known as Bioengineered Probiotic Yeast Medicines, or BioPYM™, dedicated to creating oral live biotherapeutics. This innovative platform allows probiotic yeast to operate as a micro-factory in the gut, enabling the production of therapeutic agents where they're most needed. Using BioPYM™, Fzata is working on a diverse array of proprietary drug candidates to tackle various gastrointestinal diseases and related disorders.
Additional Information and Opportunities
For those interested in learning more about Fzata, Inc.'s groundbreaking work or exploring potential collaborations, more information is available at their official website. Additionally, the company welcomes inquiries for investment opportunities and partnerships in this exciting field.
Should you have any questions or wish to discuss potential collaboration, Elizabeth Smith, PhD, MBA, the Chief Business Officer at Fzata, is the right contact. You can reach her directly via email.
Frequently Asked Questions
What is the purpose of the NIH grant awarded to Fzata, Inc.?
The NIH grant is aimed at advancing the development of FZ006, a drug candidate targeting chronic visceral pain associated with IBS.
What are the key components of the research funded by the NIH?
The grant will support IND-enabling studies, GLP toxicology, cGMP manufacturing, and clinical trial design for Phase 1 studies.
Who is leading Fzata, Inc.?
Dr. Zhiyong Yang is the President and CEO of Fzata, Inc. and plays a pivotal role in the company’s strategic direction.
What is BioPYM™?
BioPYM™ is a next-generation therapeutics platform developed by Fzata that uses probiotic yeast to create live biotherapeutics within the gut.
How can interested parties learn more about Fzata's initiatives?
More information can be found on Fzata’s official website, where further details regarding their projects and potential collaborations are available.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Tesla Confirms High Efficiency of Inductive Charging for Cybercab
- Exploring High-Yield Investments for Steady Income Growth
- Important Class Action Update for Sage Therapeutics Investors
- Investor Alert: Key October Deadline for STMicroelectronics Case
- Investing in Dividend Stocks: A Guide for Retirement Planning
- Transformative Shift at Advance Auto Parts Promises Growth
- Investing in High-Yield Dividend Stocks for Steady Income
- Strategies for Navigating Current Market Challenges
- Gilead and Merck Unveil Promising Phase 2 Data in HIV Treatment
- Evolve Bank and Trust Advances Reconciliation for End Users
Recent Articles
- ProAmpac Unveils Innovative QUADFLEX® Recyclable LFQ Packaging
- Wave Life Sciences' Impressive Interim Results Fuel Stock Surge
- Edgio Unveils Enhanced Security Features for API Protection
- Mixed Reactions to MKBHD's $50 Wallpaper App Reveal
- Mortal Kombat 1: Khaos Reigns Expansion Now Live
- Understanding Recent Shopify Options Trading Patterns
- RightCrowd Taps Sentry Interactive for Mobile Credential Solutions
- Insights into Recent Bearish Options Activity for VKTX
- One X's Strategic Shift: Redefining Completions Services
- ChannelEngine Partners with SAP for Enhanced eCommerce Solutions
- Understanding the Big Money Moves in Palantir Technologies
- Tachyum Sets Its Sights on Growth with Brno Office Launch
- MindgruveMacarta and EMARKETER Revolutionize Retail Media Data
- CSRC Reshapes Landscape for Bubble Tea IPOs in Hong Kong
- Beanstalk Benefits Expands Healthcare Options for All Workers
- Skedda Unveils New Integrations, Revolutionizing Workspaces
- Exploring Top Natural Gas Investments Amid Market Uncertainty
- Convenience Stores Enhance Fresh Food Offerings for Shoppers
- Provident Industrial Launches New Development Opportunity
- Copper-Clad Aluminum Wire: A Game Changer for Electrical Installations
- Donaldson Chairman Exercises Stock Options Valued at $1.98 Million
- DCS Corporation Elevates Chris White to Lead New Division
- Jennifer A. Beckage, Esq. Earns a Prestigious Legal Honor
- Experience Fear at the Stanley Hotel with Peacock's Overnightmare
- Ethan Johnson Joins Glazer Capital to Enhance Investment Strategies
- Speakly AI Unveils Innovative AI Solutions for Businesses
- Innovative Knee Cocoon Offers Relief After Surgery
- KINGHOOD Launches Innovative Gold ATM to Enhance Recycling Efforts
- Buddhist Monks Unite in NYC for a Week of Meditation Events
- Innovative NIH Grant Empowering Fzata, Inc. for Pain Relief Research
- Aloe Care Health Solutions Revolutionizes Elderly Care Services
- Citi Affirms Strong Outlook for Airbus with Target Price of EUR182
- Florida International University Achieves Top 50 Ranking in U.S.
- eBay Achieves 52-Week High with Impressive Growth Strategies
- Mesabi Trust Achieves 52-Week High in Stock Performance
- Sunshine Silver Mines Achieves Record Stock Growth with GATO
- JPMorgan Boosts NIO Price Target Amid New SUV Launch
- Intapp Shares Surge: Achieving 52-Week Peak in Market
- Supermicro Enhances X14 Server Lineup with New Intel Xeon CPUs
- Mag Silver Corp Reaches New Heights with Stock Performance
- Jamf Maintains Growth Amid Leadership Transition and Optimism
- BNP Paribas Eyes Growth with HSBC Acquisition Strategy
- Recent Options Activity Highlights Grocery Outlet Holding's Growth
- Significant Insider Options Exercise by GREGORY ROBERTS at A-Mark
- Donaldson's Strategic Insider Move: Becker's Stock Option Exercise
- Ashley Kavanaugh’s Strategic Move: Insights on Range Resources
- Understanding Insider Trades and Impact on Mission Produce
- Flashpoint to Sponsor Major Threat Intelligence Conference
- Understanding Sterling Infrastructure's Recent Stock Activities
- Polling Insights Suggest Matt Meyer Can Secure Delaware Governorship